Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Georg Lenz

Showing results (81-90 of 294) with videos related to

Pageof 30
Sort By:
Journal of Extracellular Vesicles|March 7, 2024
PD-L1 on large extracellular vesicles is a predictive biomarker for therapy response in tissue PD-L1-low and -negative patients with non-small cell lung cancerNadja Schöne, Marcel Kemper, Kerstin Menck, et al.
Annals of Hematology|March 25, 2026
Beta-blocker use and outcome after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemiaJohanna Werk, David Baden, Inna Shaforostova, et al.
Annals of Hematology|February 7, 2023
Amsacrine-based induction therapy in AML patients with cardiac comorbidities: a retrospective single-center analysisDavid Kuron, Alexander Pohlmann, Linus Angenendt, et al.
Oncotarget|September 22, 2021
Polyclonal on- and off-target resistance mutations in an <i>EML4-ALK</i> positive non-small cell lung cancer patient under ALK inhibitionMarcel Kemper, Georg Evers, Arik Bernard Schulze, et al.
Oncotarget|November 7, 2022
Addendum: Polyclonal on- and off-target resistance mutations in an EML4-ALK positive non-small cell lung cancer patient under ALK inhibitionMarcel Kemper, Georg Evers, Arik Bernard Schulze, et al.
Annals of Hematology|June 20, 2024
Quality of life assessment in diffuse large B-cell lymphoma (DLBCL) in REFLECT: a prospective, non-interventional, multicenter, German study, assessing Sandoz rituximab in combination with CHOPBoris Kubuschok, Burkhard Otremba, Manfred Welslau, et al.
International Journal of Cancer|September 23, 2014
Gene expression profiling of peripheral blood mononuclear cells during treatment with a gene-modified allogeneic tumor cell vaccine in advanced renal cell cancer: tumor-induced immunosuppression and a possible role for NF-κBAnne Flörcken, Michael Grau, Annette Wolf, et al.
Annals of Hematology|October 4, 2016
Epileptic seizures and rhinocerebral mucormycosis during blinatumomab treatment in a patient with biphenotypic acute leukemiaNiklas Vogt, Katharina Heß, Ralf Bialek, et al.
Blood|January 10, 2016
CARMA1- and MyD88-dependent activation of Jun/ATF-type AP-1 complexes is a hallmark of ABC diffuse large B-cell lymphomasMélanie Juilland, Montserrat Gonzalez, Tabea Erdmann, et al.
Hematological Oncology|March 15, 2026
Role of Radiotherapy in the Era of Novel Immune-Based Treatment Strategies for Multiple MyelomaTom Schlusemann, Evgenii Shumilov, Gabriele Reinartz, et al.
Pageof 30

Showing results (81-90 of 294) with videos related to

Sort By:
Pageof 30
Journal of Extracellular Vesicles|March 7, 2024
PD-L1 on large extracellular vesicles is a predictive biomarker for therapy response in tissue PD-L1-low and -negative patients with non-small cell lung cancerNadja Schöne, Marcel Kemper, Kerstin Menck, et al.
Annals of Hematology|March 25, 2026
Beta-blocker use and outcome after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemiaJohanna Werk, David Baden, Inna Shaforostova, et al.
Annals of Hematology|February 7, 2023
Amsacrine-based induction therapy in AML patients with cardiac comorbidities: a retrospective single-center analysisDavid Kuron, Alexander Pohlmann, Linus Angenendt, et al.
Oncotarget|September 22, 2021
Polyclonal on- and off-target resistance mutations in an <i>EML4-ALK</i> positive non-small cell lung cancer patient under ALK inhibitionMarcel Kemper, Georg Evers, Arik Bernard Schulze, et al.
Oncotarget|November 7, 2022
Addendum: Polyclonal on- and off-target resistance mutations in an EML4-ALK positive non-small cell lung cancer patient under ALK inhibitionMarcel Kemper, Georg Evers, Arik Bernard Schulze, et al.
Annals of Hematology|June 20, 2024
Quality of life assessment in diffuse large B-cell lymphoma (DLBCL) in REFLECT: a prospective, non-interventional, multicenter, German study, assessing Sandoz rituximab in combination with CHOPBoris Kubuschok, Burkhard Otremba, Manfred Welslau, et al.
International Journal of Cancer|September 23, 2014
Gene expression profiling of peripheral blood mononuclear cells during treatment with a gene-modified allogeneic tumor cell vaccine in advanced renal cell cancer: tumor-induced immunosuppression and a possible role for NF-κBAnne Flörcken, Michael Grau, Annette Wolf, et al.
Annals of Hematology|October 4, 2016
Epileptic seizures and rhinocerebral mucormycosis during blinatumomab treatment in a patient with biphenotypic acute leukemiaNiklas Vogt, Katharina Heß, Ralf Bialek, et al.
Blood|January 10, 2016
CARMA1- and MyD88-dependent activation of Jun/ATF-type AP-1 complexes is a hallmark of ABC diffuse large B-cell lymphomasMélanie Juilland, Montserrat Gonzalez, Tabea Erdmann, et al.
Hematological Oncology|March 15, 2026
Role of Radiotherapy in the Era of Novel Immune-Based Treatment Strategies for Multiple MyelomaTom Schlusemann, Evgenii Shumilov, Gabriele Reinartz, et al.
Pageof 30